Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
TL;DR
- Enveda, an AI-powered biotech startup, raised $311 million in a Series E funding round.
- The company's valuation reached $2 billion, doubling its valuation from 12 months prior.
- Enveda focuses on discovering drugs from natural sources such as plants and microbes.
- The startup is advancing AI-discovered drug candidates into human clinical trials.
- Current trials include drugs for severe skin conditions and maintaining weight loss after GLP-1 cessation.